Class Action Lawsuit Filed Against uniQure N.V.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ordinary shares of uniQure N.V. between September 24 and October 31, 2025, allowing potential lead plaintiffs to step forward by April 13, 2026, indicating the seriousness of the case.
- Compensation Potential: Investors joining the lawsuit may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing crucial legal support and financial security for affected investors.
- Case Details Revealed: The lawsuit alleges that uniQure failed to fully disclose that its pivotal study design was not fully approved by the FDA and that it might need to delay its Biologics License Application timeline, leading to investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, thereby enhancing investor confidence in their representation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ordinary shares of uniQure N.V. between September 24 and October 31, 2025, allowing potential lead plaintiffs to step forward by April 13, 2026, indicating the seriousness of the case.
- Compensation Potential: Investors joining the lawsuit may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing crucial legal support and financial security for affected investors.
- Case Details Revealed: The lawsuit alleges that uniQure failed to fully disclose that its pivotal study design was not fully approved by the FDA and that it might need to delay its Biologics License Application timeline, leading to investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, thereby enhancing investor confidence in their representation.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against uniQure N.V., seeking damages for investors who purchased securities between September 24 and October 31, 2025, indicating strong investor response to potential violations by the company.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which may have led investors to misjudge the company's prospects and make uninformed investment decisions.
- BLA Submission Delay Risk: The lawsuit highlights that despite claims of successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, with the omission of this information potentially exposing investors to greater financial risks.
- Investor Recourse Opportunity: Investors have until April 13, 2026, to apply to be lead plaintiffs, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
uniQure Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., particularly for investors who suffered losses exceeding $100,000 between September 24, 2025, and October 31, 2025, indicating possible legal liabilities for the company.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, which could lead to delays in future BLA submissions and impact the company's business outlook.
- Stock Price Plunge Impact: On November 3, 2025, uniQure's stock price plummeted by 49%, dropping from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, reflecting strong market concerns about the company's prospects.
- Investor Action Call: Faruqi & Faruqi LLP encourages anyone with information, including former employees and shareholders, to contact them to provide insights, indicating the firm's proactive approach to seeking legal accountability for uniQure's actions.
See More
Class Action Reminder for uniQure N.V. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, that a class action has been filed, alleging the company misled investors regarding the likelihood of FDA approval for its drug candidate.
- FDA Feedback Impact: On November 3, 2025, uniQure revealed that the FDA indicated its pivotal study design was not fully approved, necessitating a delay in the BLA submission timeline, which directly affected the company's stock price.
- Stock Price Plunge: Following the announcement, uniQure's stock price plummeted by $33.40, a drop of over 49%, from a closing price of $67.69 on October 31, 2025, to $34.29, reflecting strong market concerns about the company's future prospects.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 13, 2026, indicating their representation of other shareholders' interests, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected shareholders to participate, thereby amplifying the lawsuit's impact.
- Details of Allegations: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which could delay its Biologics License Application, thereby affecting the company's future market prospects and operational credibility.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the potential outcomes of this lawsuit.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements, failing to secure full FDA approval for its pivotal study, resulting in investor losses once the truth emerged.
- Legal Consultation Opportunity: Investors are encouraged to contact the Schall Law Firm before April 13, 2026, to discuss their rights and participate in the lawsuit, with free consultations available.
- Lawsuit Certification Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ordinary shares of uniQure N.V. between September 24 and October 31, 2025, allowing potential lead plaintiffs to step forward by April 13, 2026, indicating the seriousness of the case.
- Compensation Potential: Investors joining the lawsuit may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing crucial legal support and financial security for affected investors.
- Case Details Revealed: The lawsuit alleges that uniQure failed to fully disclose that its pivotal study design was not fully approved by the FDA and that it might need to delay its Biologics License Application timeline, leading to investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, thereby enhancing investor confidence in their representation.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against uniQure N.V., seeking damages for investors who purchased securities between September 24 and October 31, 2025, indicating strong investor response to potential violations by the company.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which may have led investors to misjudge the company's prospects and make uninformed investment decisions.
- BLA Submission Delay Risk: The lawsuit highlights that despite claims of successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, with the omission of this information potentially exposing investors to greater financial risks.
- Investor Recourse Opportunity: Investors have until April 13, 2026, to apply to be lead plaintiffs, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
uniQure Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., particularly for investors who suffered losses exceeding $100,000 between September 24, 2025, and October 31, 2025, indicating possible legal liabilities for the company.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, which could lead to delays in future BLA submissions and impact the company's business outlook.
- Stock Price Plunge Impact: On November 3, 2025, uniQure's stock price plummeted by 49%, dropping from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, reflecting strong market concerns about the company's prospects.
- Investor Action Call: Faruqi & Faruqi LLP encourages anyone with information, including former employees and shareholders, to contact them to provide insights, indicating the firm's proactive approach to seeking legal accountability for uniQure's actions.
See More
Class Action Reminder for uniQure N.V. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, that a class action has been filed, alleging the company misled investors regarding the likelihood of FDA approval for its drug candidate.
- FDA Feedback Impact: On November 3, 2025, uniQure revealed that the FDA indicated its pivotal study design was not fully approved, necessitating a delay in the BLA submission timeline, which directly affected the company's stock price.
- Stock Price Plunge: Following the announcement, uniQure's stock price plummeted by $33.40, a drop of over 49%, from a closing price of $67.69 on October 31, 2025, to $34.29, reflecting strong market concerns about the company's future prospects.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 13, 2026, indicating their representation of other shareholders' interests, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected shareholders to participate, thereby amplifying the lawsuit's impact.
- Details of Allegations: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which could delay its Biologics License Application, thereby affecting the company's future market prospects and operational credibility.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the potential outcomes of this lawsuit.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements, failing to secure full FDA approval for its pivotal study, resulting in investor losses once the truth emerged.
- Legal Consultation Opportunity: Investors are encouraged to contact the Schall Law Firm before April 13, 2026, to discuss their rights and participate in the lawsuit, with free consultations available.
- Lawsuit Certification Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
